Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?

Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?

Advancements and the use of tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of Chronic Myeloid Leukemia (CML), achieving unprecedented success rates and expanding their applications to various neoplasms. However, the use of TKIs is not without its drawbacks. Skin, gastrointestina...

Full description

Bibliographic Details
Main Authors: Alexander Yakobson, Ala Eddin Neime, Omar Abu Saleh, Kayed Al Athamen, Walid Shalata
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Clinics and Practice
Subjects:
bullous pemphigoid
dermato-toxicity
tyrosine kinase inhibitors (TKI’s)
imatinib (Gleevec)
chronic myeloid leukemia (CML)
Online Access:https://www.mdpi.com/2039-7283/13/5/96

Similar Items

Similar Items